These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24418117)

  • 1. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 2. [Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?].
    Hureaux J; Couturier O; Lacœuille F; Bouchet F; Chouaïd C; Saulnier P; Urban T;
    Rev Mal Respir; 2016 Nov; 33(9):817-823. PubMed ID: 27257103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
    Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
    J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
    Kumar K; Singh H; Gupta RK; Bal C; Kumar R
    Clin Nucl Med; 2015 Apr; 40(4):e251-2. PubMed ID: 25275420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
    Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z
    Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
    Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD; Kim S; Saba NF; Pickens A; Behera M; Fu RW; Rossi MR; Auffermann WF; Torres WE; Bechara R; Deng X; Sun SY; Fu H; Gal AA; Khuri FR
    Clin Cancer Res; 2015 Apr; 21(8):1859-68. PubMed ID: 25673697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[
    Abdulla DSY; Scheffler M; Brandes V; Ruge M; Kunze S; Merkelbach-Bruse S; Nogova L; Michels S; Fischer R; Riedel R; Büttner R; Persigehl T; Grau S; Galldiks N; Drzezga A; Kobe C; Wolf J
    Clin Lung Cancer; 2019 Mar; 20(2):e148-e151. PubMed ID: 30528316
    [No Abstract]   [Full Text] [Related]  

  • 12. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI.
    de Langen AJ; van den Boogaart V; Lubberink M; Backes WH; Marcus JT; van Tinteren H; Pruim J; Brans B; Leffers P; Dingemans AM; Smit EF; Groen HJ; Hoekstra OS
    J Nucl Med; 2011 Jan; 52(1):48-55. PubMed ID: 21149474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micropapillary pattern in lung adenocarcinoma: aspect on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
    Prior JO; Stupp R; Christodoulou M; Letovanec I
    Interact Cardiovasc Thorac Surg; 2010 Jan; 10(1):144-5. PubMed ID: 19875512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
    Zander T; Scheffler M; Nogova L; Kobe C; Engel-Riedel W; Hellmich M; Papachristou I; Toepelt K; Draube A; Heukamp L; Buettner R; Ko YD; Ullrich RT; Smit E; Boellaard R; Lammertsma AA; Hallek M; Jacobs AH; Schlesinger A; Schulte K; Querings S; Stoelben E; Neumaier B; Thomas RK; Dietlein M; Wolf J
    J Clin Oncol; 2011 May; 29(13):1701-8. PubMed ID: 21422426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidental finding of an endobronchial tumor by 18F-FDG PET/CT.
    Navales I; Garcia JR; Alvarez-Moro FJ; Navarro A; Escobar I; Lomeña F
    Rev Esp Med Nucl Imagen Mol; 2013; 32(4):271-2. PubMed ID: 23046638
    [No Abstract]   [Full Text] [Related]  

  • 19. Preoperative pathological diagnosis of lung cancer: is it always necessary?
    Nakajima J
    Ann Thorac Cardiovasc Surg; 2012; 18(3):183-5. PubMed ID: 22673553
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy.
    Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
    Eur J Radiol; 2011 Jan; 77(1):92-6. PubMed ID: 19695804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.